Cargando…
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering. The rapid adoption...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127450/ https://www.ncbi.nlm.nih.gov/pubmed/34002066 http://dx.doi.org/10.1038/s41577-021-00547-6 |
_version_ | 1783693951047303168 |
---|---|
author | Morris, Emma C. Neelapu, Sattva S. Giavridis, Theodoros Sadelain, Michel |
author_facet | Morris, Emma C. Neelapu, Sattva S. Giavridis, Theodoros Sadelain, Michel |
author_sort | Morris, Emma C. |
collection | PubMed |
description | A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering. The rapid adoption of novel, patient-specific cellular therapies builds on scientific developments in tumour immunology, genetic engineering and cell manufacturing, best illustrated by the curative potential of chimeric antigen receptor (CAR) T cell therapy targeting CD19-expressing malignancies. However, the clinical benefit observed in many patients may come at a cost. In up to one-third of patients, significant toxicities occur that are directly associated with the induction of powerful immune effector responses. The most frequently observed immune-mediated toxicities are cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This Review discusses our current understanding of their pathophysiology and clinical features, as well as the development of novel therapeutics for their prevention and/or management. |
format | Online Article Text |
id | pubmed-8127450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81274502021-05-18 Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy Morris, Emma C. Neelapu, Sattva S. Giavridis, Theodoros Sadelain, Michel Nat Rev Immunol Review Article A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering. The rapid adoption of novel, patient-specific cellular therapies builds on scientific developments in tumour immunology, genetic engineering and cell manufacturing, best illustrated by the curative potential of chimeric antigen receptor (CAR) T cell therapy targeting CD19-expressing malignancies. However, the clinical benefit observed in many patients may come at a cost. In up to one-third of patients, significant toxicities occur that are directly associated with the induction of powerful immune effector responses. The most frequently observed immune-mediated toxicities are cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This Review discusses our current understanding of their pathophysiology and clinical features, as well as the development of novel therapeutics for their prevention and/or management. Nature Publishing Group UK 2021-05-17 2022 /pmc/articles/PMC8127450/ /pubmed/34002066 http://dx.doi.org/10.1038/s41577-021-00547-6 Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Morris, Emma C. Neelapu, Sattva S. Giavridis, Theodoros Sadelain, Michel Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy |
title | Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy |
title_full | Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy |
title_fullStr | Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy |
title_full_unstemmed | Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy |
title_short | Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy |
title_sort | cytokine release syndrome and associated neurotoxicity in cancer immunotherapy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127450/ https://www.ncbi.nlm.nih.gov/pubmed/34002066 http://dx.doi.org/10.1038/s41577-021-00547-6 |
work_keys_str_mv | AT morrisemmac cytokinereleasesyndromeandassociatedneurotoxicityincancerimmunotherapy AT neelapusattvas cytokinereleasesyndromeandassociatedneurotoxicityincancerimmunotherapy AT giavridistheodoros cytokinereleasesyndromeandassociatedneurotoxicityincancerimmunotherapy AT sadelainmichel cytokinereleasesyndromeandassociatedneurotoxicityincancerimmunotherapy |